Korro Bio registers Phase 1/2 trial of KRRO-121 for urea cycle disorders
Korro Bio listed a new first-in-human study of its RNA-editing candidate KRRO-121 in healthy volunteers and patients with urea cycle disorders, not yet recruiting.
Korro Bio had one trial registration of note this week.
- Korro Bio registered a Phase 1/2 study, called "ANCHOR" (NCT07773246), testing KRRO-121 given as a subcutaneous injection1 against placebo in healthy volunteers and in patients with urea cycle disorders. The drug is an RNA editing oligonucleotide conjugated to GalNAc that is being developed for hyperammonemia in patients with urea cycle disorders.1 The study is designed so that the trial name stands for "AssessmeNt of Control of Hyperammonemia through Oligonucleotide-based RNA editing."1 The record lists an estimated enrollment of 30 participants1 and is not yet recruiting1, with a single site in Melbourne, Australia.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.